Sp1298
FROM EPIDEMIOLOGY TO ENDPOINTS: EVOLVING PERSPECTIVES ON EOSINOPHILIC ESOPHAGITIS (EOE) MEDICAL SYMPOSIUM
Date
May 21, 2024
Presenters
University of North Carolina School of Medicine
Northwestern University - The Feinberg School of Medicine
Tracks
Related Products
EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
PANEL DISCUSSION
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed…
DUPILUMAB IS EFFICACIOUS IN EOSINOPHILIC ESOPHAGITIS REGARDLESS OF PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY-EOE-TREET STUDY
BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
CASED BASED DISCUSSION
SOCIETY: AGA
